title: Serum concentrations of growth factors in women with and without endometriosis: the action of anti-endometriosis medicines.
abstract: Endometriosis is a common gynecologic syndrome of unknown etiology and pathogenesis. Growth factors and inflammatory mediators produced by peritoneal leukocytes have recently been postulated to participate in the pathogenesis of endometriosis. Angiogenic factors released from peritoneal macrophages may also play a role in the development of this disease. In the present study, we investigate the soluble levels of vascular endothelial growth factor (VEGF), epidermal growth factor-receptor (EGF-R), granulocyte/macrophage-colony stimulating factor (GM-CSF), Insulin-like growth factor-1 (IGF-1) and interferon-gamma (IFN-gamma) in the serum of 28 women with and 20 without endometriosis. We also compared these levels before, during and after treatment with danazol and leuprorelin acetate depot, the two therapeutic regiments of choice concerning this disease. We found that only sVEGF levels were higher in women with endometriosis in comparison to controls (P < 0.001) while sEGF-R is not present. GM-CSF, IGF-1 and IFN-gamma soluble levels are not affected in either healthy or endometriotic subjects. The 6-month treatment with danazol decreased sVEGF levels (P < 0.02) and increased sEGF-R levels (P < 0.001). These observations support the view that VEGF may be associated with the disease process and that danazol may bring sVEGF levels to a normal threshold. However, future studies will be focused on the anti-angiogenic control of the action of VEGF in patients with endometriosis.
authors.affiliation: Department of Obstetrics and Gynecology, University of Crete, PO Box 1393, 714-09 Heraklion, Crete, Greece.
authors.forename: I M
authors.initials: IM
authors.lastname: Matalliotakis
authors.forename: A G
authors.initials: AG
authors.lastname: Goumenou
authors.forename: G E
authors.initials: GE
authors.lastname: Koumantakis
authors.forename: M A
authors.initials: MA
authors.lastname: Neonaki
authors.forename: E E
authors.initials: EE
authors.lastname: Koumantakis
authors.forename: E
authors.initials: E
authors.lastname: Dionyssopoulou
authors.forename: I
authors.initials: I
authors.lastname: Athanassakis
authors.forename: S
authors.initials: S
authors.lastname: Vassiliadis
mesh_terms: D000328:Adult; D003613:Danazol / Q000627:therapeutic use; D003692:Delayed-Action Preparations; D004715:Endometriosis / Q000097:blood* / Q000188:drug therapy*; D016228:Endothelial Growth Factors / Q000097:blood; D066246:ErbB Receptors / Q000097:blood; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000097:blood; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D036341:Intercellular Signaling Peptides and Proteins / Q000097:blood; D007371:Interferon-gamma / Q000097:blood; D016729:Leuprolide / Q000008:administration & dosage / Q000627:therapeutic use; D008222:Lymphokines / Q000097:blood; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
chemical_list: D003692:Delayed-Action Preparations; D016228:Endothelial Growth Factors; D036341:Intercellular Signaling Peptides and Proteins; D008222:Lymphokines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D007334:Insulin-Like Growth Factor I; D007371:Interferon-gamma; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D066246:ErbB Receptors; D016729:Leuprolide; D003613:Danazol